Making LDL Make Sense

Making LDL Make Sense: A Guideline-Based Roadmap for Primary and Specialty Care Clinicians

A CME/CE Webinar and Enduring Activity

November 17, 2025 | 6:00 PM Central

Join expert faculty for this free CME/CE webinar and enduring activity designed to help primary care providers optimize LDL-C management and improve patient outcomes.

CLICK HERE to Scroll Directly to the Registration Form

Faculty

• Kaye-Eileen Willard, MD, FNLA
• Mary Katherine Cheeley, PharmD, CLS, FNLA
• Dinesh Kalra, MD, MBA, FNLA
• Lauren Williams, MCN, RDN, LD
• Susan Halli Demeter, DNP, CLS, FNLA

Agenda

• Current Trends in ASCVD Management
  1. Overview of increasing rates of ASCVD
  2. Importance of LDL-C as a biomarker of ASCVD
  3. Include notes about multitude of guidelines for management and the importance of common guidance

• Basic Screening Guidelines
  1. Children
  2. Adults
  3. Those on Lipid Therapy
• Targets for Adults
  1. Healthy Adults
  2. High Risk
  3. Very High Risk
  4. Addressing the safety of low LDL-C levels
• Lipid Lowering Options
  1. Lifestyle Modifications
     • Nutrition/ exercise
     • Importance of managing expectations of diet and exercise related reductions
  2. Pharmacologic Treatment Options
     • Statins
       1. Briefly cover statin intolerance
     • Non-Statins (ezetimibe, PCSK9 inhibitors, and others)
     • Address outdated and infrequently used non-statins (bile acid sequestrants/ Niacin)

 

Endorsed by:

 

Program Overview
Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death in the United States and globally, accounting for approximately 25% of all deaths in the U.S. alone. Despite advances in care, recent trends show a troubling reversal in the decades-long decline in cardiovascular mortality, a shift largely attributed to the underutilization of effective therapies, particularly among individuals with elevated low-density lipoprotein cholesterol (LDL-C). This gap in treatment underscores the urgent need for targeted education that supports evidence-based, practical strategies for risk reduction.

To address this need, the National Lipid Association (NLA) has developed LDL Management Simplified, a new publication designed to clarify and streamline the often-complex landscape of cholesterol management guidelines. This resource distills current recommendations into a focused, actionable format that aligns with the realities of today’s clinical practice where time is limited, and clinical priorities are numerous. Accompanied by a clinician–patient worksheet, the publication empowers clinicians to assess and discuss LDL-C–related risk factors with patients in a meaningful and time-efficient way.

Through this multi-activity educational program, we aim to equip healthcare clinicians with the tools and knowledge necessary to apply guideline-directed LDL-C management confidently and consistently. By translating simplified recommendations into clinical action, this program seeks to reduce ASCVD risk and drive measurable improvements in patient outcomes.

Target Audience
This course is designed for cardiologists, endocrinologists, primary care physicians, physicians, dietitians, pharmacists, nurses, physician assistants, and other health care professionals who want to enhance or develop the knowledge and skills necessary to provide optimal care to patients with dyslipidemias and related conditions.

Type of Activity
Internet Live Activity
Knowledge

Educational Objective(s)
At the conclusion of this activity, all participants should be able to:

• Describe current screening guidelines for primary and secondary prevention for atherosclerotic CVD (ASCVD)
• Summarize current treatment guidelines for hypercholesterolemia
• Devise treatment plans to manage patients with ASCVD who have elevated LDL-C levels
• Assess newer and emerging nonstatin agents, including clinical trial data, for the management of hypercholesterolemia
• Describe the importance of lifestyle modification in the treatment of hypercholesterolemia
• Discuss the role of team-based care for optimal management of patients with lipid disorders

 

CRITERIA FOR SUCCESS
Statements of credit will be awarded based on the participant’s attendance and submission of the activity evaluation form. Partial credit may be awarded for ACPE credit.  A statement of credit will be available upon completion of an online evaluation/claimed credit form at https://www.surveymonkey.com/r/ldlsimplified. The deadline to claim credit is December 18, 2025. Questions related to this content should be sent to cme@lipid.org.

COMMERCIAL SUPPORT
This program is supported by independent educational grants from the following companies
NewAmsterdam Pharma B.V., Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc.

CREDIT DESIGNATION
CME/CE credit provided by the National Lipid Association

In support of improving patient care, The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Credit Designation Statement
The National Lipid Association designates this live internet activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

 

Pharmacist Accreditation Statement
Universal Activity Number UAN JA0007192-0000-25-028-L01-P (Knowledge)
This Activity has been approved for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education.

Nursing
The maximum number of hours awarded for this CE activity is 1.0 contact hours.

 

DISCLOSURE INFORMATION
FACULTY, PLANNERS, & REVIEWERS

Kaye-Eileen Willard, MD, FNLA
Has nothing to disclose.

Dinesh Kalra, MD, MBA, FNLA
Has nothing to disclose.

Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Consultant/Sub-Investigator – Novartis
Consultant – Regeneron
Sub-Investigator – Eli Lilly

Lauren Williams, MCN, RDN, LD
Speaker – Kanedka - Liposorber

Susan Halli Demeter, DNP, CLS, FNLA
Has nothing to disclose.

NLA Staff
Has nothing to disclose.

DISCLOSURE OF UNLABELED USE AND INVESTIGATIONAL PRODUCTS
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLOSURE DECLARATION
It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. Planners, faculty, reviewers, and staff have disclosed any financial relationships with commercial interests as defined by the ACCME. 

DISCLAIMER
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.

PERMISSIONS
The National Lipid Association acknowledges that permissions have been obtained for use of all copyrighted materials, including graphs, tables, pictures, and charts printed in this activity syllabus. Permissions have also been obtained from identifiable patients in photographs and other images, consistent with the DHHS HIPAA regulations for individual privacy.

Click Here to Register